Understanding glycopeptide isomers and their role in diseases
Official title: Quantitative Characterization of Glycopeptide Isomers
Funded at Texas Tech University · NIH-11009564 · Data updated 2026-11-12
This study is looking at how certain sugar molecules on proteins, called glycopeptide isomers, affect our immune system and diseases like Alzheimer's and COVID-19, with the goal of finding better treatments for these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Tech University NIH-funded |
| Lab location | 1 site (Lubbock, United States) |
| Project start | February 1, 2019 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $296,063 |
| NIH project number | 5R01GM130091-07 |
| Project ID | NIH-11009564 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or those affected by COVID-19.
✕Less likely to help
Patients with conditions unrelated to glycosylation or those not diagnosed with Alzheimer's or COVID-19 may not benefit from this research.
What this research studies
This research investigates the biological functions of glycosylation, which is crucial for immune responses, cell development, and interactions between hosts and pathogens. It focuses on characterizing glycopeptide isomers, particularly their role in diseases like Alzheimer's and COVID-19. The researchers will employ advanced techniques such as mesoporous graphitized carbon liquid chromatography-mass spectrometry (MGC-LC-MS) and novel derivatization methods to enhance the identification and quantification of these isomers. By improving the understanding of glycopeptide isomers, the research aims to contribute to the development of targeted therapies for various diseases.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for diseases associated with abnormal glycosylation, including Alzheimer's disease and COVID-19.
How similar studies have gone: Previous research has shown promising results in understanding glycosylation's role in various diseases, indicating that this approach has potential for success.
Where this research is happening
-
Texas Tech University
Lubbock, United States Active
Researchers
- Principal investigator: Mechref, Yehia — Texas Tech University
- Study coordinator: Mechref, Yehia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.